EMA Authorised: Tecentriq (atezolizumab) — Roche Registration GmbH

View source ↗

Summary

Roche's Tecentriq (atezolizumab) has been authorised by the EMA for multiple indications including transitional cell carcinoma, non-small cell lung cancer, urol…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms
• Non-small Cell Lung Cancer
• Small Cell Lung Carcinoma
• Transitional Cell Carcinoma
• Urologic Neoplasms

Drugs mentioned

• Tecentriq (atezolizumab)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Transitional Cell;Carcinoma, Non-Small-Cell Lung;Urologic Neoplasms;Breast Neoplasms;Small Cell Lung Carcinoma. MAH: Roche Registration GmbH. Decision date: 18/06/2026